Intellia Therapeutics Stock Plunge: Don’t Buck Mr. Market (NASDAQ:NTLA)

Summary

Intellia Therapeutics fell 20.5% the day after it reported Phase 2 test results for a promising treatment.
You’d think, from the reaction, that the news was bad.
Actually, it was quite the opposite… the results were good, and the treatment is advancing to Phase 3.
Naturally, reasons for the selloff were given, but I find them very flimsy.
It’s tempting to bottom fish here, but I don’t recommend that until we get another (upside) catalyst.

Angry Adult — kiankhoon/iStock via Getty Images

I get it. Biotech is risky.

Drug discovery, getting approvals, new competitive drugs… So many things can go wrong. And for investors, developments can be harder to predict than for most stocks.

True some such

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.